Related references
Note: Only part of the references are listed.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
Robert D. Morgan et al.
LANCET ONCOLOGY (2021)
Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group
P. Corbaux et al.
ANNALS OF ONCOLOGY (2021)
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas
Benoit You et al.
CANCER TREATMENT REVIEWS (2021)
Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.
Benoit You et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Benoit You et al.
CLINICAL CANCER RESEARCH (2020)
The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
B. You et al.
ANNALS OF ONCOLOGY (2020)
The prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands
L. Van Wagensveld et al.
ANNALS OF ONCOLOGY (2020)
PROGNOSTIC VALUE AND ASSOCIATION WITH VELIPARIB BENEFIT OF MODELED CA-125 ELIMINATION KINETICS (KELIM) IN PATIENTS WITH NEWLY DIAGNOSED OVARIAN CANCER: ANALYSIS FROM THE VELIA/GOG-3005 STUDY
B. You et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)
Olivier Colomban et al.
JNCI CANCER SPECTRUM (2020)
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
Peter G. Rose et al.
OBSTETRICS AND GYNECOLOGY (2019)
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study
Olivier Colomban et al.
CLINICAL CANCER RESEARCH (2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.
Gwenael Ferron et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1027PEarly prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)
O Colomban et al.
ANNALS OF ONCOLOGY (2019)
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
S. Intidhar Labidi-Galy et al.
GYNECOLOGIC ONCOLOGY (2019)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
Andrew R. Clamp et al.
LANCET (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Epidemiology of ovarian cancer: a review
Brett M. Reid et al.
CANCER BIOLOGY & MEDICINE (2017)
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602
Takashi Onda et al.
EUROPEAN JOURNAL OF CANCER (2016)
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
Anna Fagotti et al.
EUROPEAN JOURNAL OF CANCER (2016)
The biological effects and clinical implications of BRCA mutations: where do we go from here?
Dominique Stoppa-Lyonnet
EUROPEAN JOURNAL OF HUMAN GENETICS (2016)
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Alexi A. Wright et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Sean Kehoe et al.
LANCET (2015)
Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer
Rosemary D. Cress et al.
OBSTETRICS AND GYNECOLOGY (2015)
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment
R. Almufti et al.
ANNALS OF ONCOLOGY (2014)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer
Pierre-Emmanuel Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study)
Benoit You et al.
GYNECOLOGIC ONCOLOGY (2013)
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
Suk-Joon Chang et al.
GYNECOLOGIC ONCOLOGY (2013)
Longitudinal Screening Algorithm That Incorporates Change Over Time in CA125 Levels Identifies Ovarian Cancer Earlier Than a Single-Threshold Rule
Charles W. Drescher et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer
Jian-Lun Xu et al.
GYNECOLOGIC ONCOLOGY (2012)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer
Chee K. Lee et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer
Andreas du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois et al.
CANCER (2009)
The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer
Rodney P. Rocconi et al.
GYNECOLOGIC ONCOLOGY (2009)
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
A. Prat et al.
ANNALS OF ONCOLOGY (2008)
Modelling response time profiles in the absence of drug concentrations: Definition and performance evaluation of the K-PD model
P. Jacqmin et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
The real-life variability of CA-125 in ovarian cancer patients
Elisa Tso et al.
GYNECOLOGIC ONCOLOGY (2006)
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer:: A gynecologic cancer intergroup trial of the AGO-OVAR and GINECO
Jacobus Pfisterer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study
J. M. Riedinger et al.
ANNALS OF ONCOLOGY (2006)
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
GJS Rustin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
JP Neijt et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
